A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients with Recurrent Cutaneous Squamous Cell Carcinoma (CSCC)
Clinical Trial Grant
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
August 20, 2019
End Date
June 11, 2025
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
August 20, 2019
End Date
June 11, 2025